• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GSK dodges bullet after another generic Advair competitor is denied

May 11, 2017 By Sarah Faulkner

GlaxoSmithKlineGlaxoSmithKline (NYSE:GSK) will not likely face generic competition to its lung drug Advair in the US this year. Yesterday, the FDA denied the application for a 2nd generic competitor.

Hikma Pharmaceuticals (LON:HIK) disclosed today that the FDA decided not to approve its version of the inhaled asthma treatment, due to “major” problems with the application. This comes on the heels of Mylan‘s (NSDQ:MYL) announcement in March that the federal watchdog delayed approval of its Advair generic.

Thanks to these 2 rejections, industry analysts believe that the threat of generic competition has been pushed back until next year, according to Reuters. 

Both Hikma and Mylan received complete response letters from the FDA that were categorized as major. A major amendment to a generic drug application comes with a delay of 10 months for an updated FDA response.

Hikma said it was reviewing the FDA’s response. Yesterday, Mylan said it disagreed with the reasoning behind the agency’s decision. The company said the FDA was asking Mylan to comply with draft guidance, rather than rules that the 2 parties previously agreed upon.

The threat of an Advair competitor is the 1st big challenge for GSK’s new chief executive, Emma Walmsley. Although the company has a number of new respiratory drugs, any generic competition will likely hit profits, since the drug generates high margins.

GSK said that without a generic competitor for Advair in the U.S. this year, it expects adjusted earnings per share to rise by 5-7% in 2017.

Last year, Advair brought in $2.37 billion in sales in the U.S.

Material from Reuters was used in this report.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, hikmapharmaceuticals, Mylan

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS